Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan

Published: Thursday, January 30, 2014
Last Updated: Thursday, January 30, 2014
Bookmark and Share
Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines.

Horizon Discovery™ announce that it has entered into a large-scale licensing agreement with a Japanese medical university. The agreement covers a limited use label license for academic use of 250 of Horizon’s X-MAN™ genetically defined, isogenic cell lines, and demonstrates the global recognition of the company’s in vitro disease models.

Horizon’s X-MAN isogenic cell lines accurately model the disease-causing mutations found in patients with cancer, and increasingly other diseases. Horizon creates these cell lines using its precision genome-editing GENESIS™ platform, consisting of rAAV, ZFN and CRISPR technologies, to engineer specific disease-related mutations. These models help researchers understand how complex genetic diseases manifest themselves in patients, and can reduce the cost of bringing to market new personalized therapies by streamlining many aspects of drug development including target identification, target validation, assay development, drug screening, lead optimization, and biomarker-driven clinical trial design.

Kam Dhaliwal, VP Sales, Horizon Discovery, commented: “This is a very significant deal for Horizon Discovery, covering a large number of cell lines and representing a large investment by the university. We are delighted that our distribution partnership in Japan with Summit Pharmaceuticals International (SPI) is proving so productive.  Summit has proven to be extremely effective in opening the Japanese market for Horizon and we anticipate further adoption of our products and services in Japan in the future.”

The director of the Translational Research Centre at the university commented: “Horizon’s X-MAN cell lines offer a unique and valuable resource for the study of specific, disease-related mutations. We are look forward to applying the X-MAN technology in our research projects.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Horizon Discovery CEO Wins Executive of the Year
Darrin Disley wins Executive of the Year award at the SCRIP Awards.
Thursday, December 04, 2014
Horizon Discovery Group plc Establishes Scientific Advisory Board for Horizon Diagnostics Business Unit
The Scientific Advisory Board will recommend improvements needed in laboratories adopting Companion Diagnostic assays.
Tuesday, November 11, 2014
Horizon Acquires Sage Labs Inc. for $48M (£29M)
Acquisition makes Horizon the world’s leading gene-editing and translational genomics company.
Wednesday, October 01, 2014
Horizon Reports a Strong First Half
Interim results for the six months ended 30 June 2014 position the company for continued growth.
Tuesday, September 23, 2014
Horizon to Acquire CombinatoRx Service Business and Assets from Zalicus
Horizon Discovery Group has agreed to acquire the CombinatoRx service business and related assets from Zalicus Inc for £4.7M.
Thursday, May 15, 2014
Horizon, Sirion Sign Supply and Distribution Agreement
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Monday, February 17, 2014
Dr. Ian Gilham Appointed Chairman of the Board for Horizon Discovery
Chairman’s healthcare industry career spans thirty years, encompassing all aspects of successful company growth and development.
Tuesday, January 14, 2014
Horizon, AstraZeneca Announce Oncology Agreement
Research, collaboration and license agreement to explore a range of oncology-relevant genotypes.
Tuesday, January 07, 2014
Horizon Discovery and Desktop Genetics Collaborate on CRISPR Design Platform
Platform to be used as part of Horizon’s GENESIS suite of gene editing technologies.
Tuesday, December 17, 2013
Horizon Discovery CEO Joins UKTI Delegation to India Led by David Cameron
Senior business and political leaders from India and Europe meet at Prabodhan Leaders’ Conclave.
Tuesday, November 26, 2013
Horizon Licenses ZFN Gene Editing Technology from Sigma-Aldrich
Horizon to utilize both nuclease and rAAV gene editing platforms in custom cell-line generation services and creation of genetically-defined cell line products.
Tuesday, September 03, 2013
Horizon Strengthens Board with Appointment of Dr. Ian Gilham
Appointment of Dr. Ian Gilham as non-executive director.
Friday, August 02, 2013
Scientific News
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
How to Unlock Inaccessible Genes
An international team of biologists has discovered how specialized enzymes remodel the extremely condensed genetic material in the nucleus of cells in order to control which genes can be used.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Mapping Regulatory Elements
Systematically searching DNA for regulatory elements indicates limits of previous thinking
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!